ClinicalTrials.gg
Status unknownNCT05550285Updated Sep 22, 2022

3D Printed Titanium Mesh vs Guided Autogenous Graft

A Phase 2/3 interventional study of orbital floor recontriction in Orbital Floor (Blow-Out) Open Fracture and Enophthalmos Traumatic, sponsored by Mohammed Ghassan Mohammed Shaalan. Status unknown at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2022-09-22.

Sponsored by Mohammed Ghassan Mohammed Shaalan · Phase 2/3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Sep 2022), so the status shown — last known as Enrolling by invitation — may be out of date.

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Sep 2021, registered Sep 2022).
Phase
Phase 2/3
Study type
Interventional
Enrollment
32
Allocation
Randomized
Sex
All
01

Study summary

In this study, the hypothesis states that there is no significant difference between specified populations. In our case, the 3D printed patient-specific titanium mesh is thought to have the same effect and results in comparison with the computer-guided calvarial bone graft technique according to the related studies.

Read the detailed description

Recruitment:

Patients' data will be enrolled in the database of the Outpatient clinics of the Department of Oral \& Maxillofacial Surgery, Faculty of Dentistry, Cairo University

  • If there is potential eligibility, the patient will be examined thoroughly as described before.
  • Consecutive sampling is done through screening of patients. This will continue until the target population is achieved.
  • Identifying and recruiting potential subjects is achieved through a patient database

Pre-operative data Collection:

All Patients will undergo CT scan and throughout medical history will be taken. Enophthalmos and orbital volume will be measured via CT data using DICOM viewers, the anterior orbital boundary is defined by a line joining the zygomatico-frontal process on each side. Cross-sectional area is measured using the region of interest (ROI) facility, after tracing the orbital outline The degree of enophthalmos is assessed by measuring the distance between the posterior surface of each lens and the anterior orbital boundary line.

Exophthalmometer The instrument is placed on the lateral orbital rim of each side, using as small of a base as possible, the device measures the distance between the lateral orbital rim and the most anterior position of the cornea.

For Both Groups, the retrieved DICOM files of the CT scan will be imported in a DICOM (Digital Imaging and Communications in Medicine) viewer software (Mimics 19.0; Mimics Medical 19.0, Materialise, Leuven, Belgium) and segmentation will be done starting from thresholding and region growing to form a mask for the area of interest.

For Control Group, the orbital defect outline will be identified and measured and the same measurements will be transferred to the parietal bones bilaterally taking into consideration that they must be in the thickest portion of the parietal bone to construct the surgical guide prior to surgery. A three-dimensional model of the patient's skull will be calculated from the selected mask; the skull model will be manufactured and printed and will be used to assure seating of the Autogenous graft intra-operatively before inserting it in the surgical field.

For Study Group, the orbital floor defect will be digitally reconstructed by mirroring an individually defined 3-dimensional (3D) segment from the unaffected side onto the deformed side to determine the locations and range of orbital defects. The Standard Template Library data transformed from the 3D data will be used in the creation computer-assisted 3D Printed titanium mesh implant. The implants will be designed based on the PorousiTi structure which was created to replicate the mechanical properties of human bone. Anatomical obstacles including infra-orbital nerve and lacrimal duct were taken into account during this process.

Intra operative procedures for both groups: A vasoconstrictor will be injected under the conjunctiva to aid in hemostasis, Additional solution will be infiltrated during the lateral canthotomy. A corneal shield will be placed to protect the globe and the lower eyelid will be everted with fine forceps and two or three traction sutures will be placed through the eyelid. These sutures will be placed straight through the eyelid, from palpebral conjunctiva to skin, approximately 4 to 5 mm below the eyelid margin to ensure that the tarsal plate is included in the suture.

When a lateral canthotomy is indicated, the canthotomy will be the initial incision. One tip of the pointed scissors is inserted within the palpebral fissure, extending laterally to the depth of the underlying lateral orbital rim (approximately 7 to 10 mm). The scissors are used to cut horizontally through the lateral palpebral fissure. The structures that are cut in the horizontal plane are the skin, orbicularis oculi muscle, orbital septum, lateral canthal tendon, and conjunctiva.

The traction sutures are used to evert the lower eyelid. The lower eyelid is still tethered to the lateral orbital rim by the inferior limb of the lateral canthal tendon. The tendon, which is easily visualized with eyelid retraction, will be released with a sharp vertical cut. When performing the cantholysis, the scissors must be positioned with a vertical orientation. After cantholysis, the lower eyelid will be immediately freed from the lateral orbital rim, making the eversion more effective.

After the lower eyelid is everted, the position of the lower tarsal plate through the conjunctiva will be noted. Incising in the conjunctiva, blunt-tipped pointed scissors are used to dissect through the small incision in the conjunctiva made during the lateral canthotomy, inferiorly toward the infraorbital rim. Traction sutures are used to evert the lower eyelid during the dissection. The scissors are spread to clear a pocket posterior to the orbital septum, ending just posterior to the orbital rim Scissors are used to incise the conjunctiva and lower eyelid retractors midway between the inferior margin of the tarsal plate and the inferior conjunctival fornix. The incision can be extended as far medially as necessary for the surgery but must not violate the lacrimal sac.

The incised edge of the vestibular conjunctiva can be dissected free, providing a location for a traction suture to hold the corneal shield in place.

After retracting the orbital contents internally and the lower eyelid externally, using suitable retractors, the periorbita will be sharply incised, avoiding the lacrimal sac medially. During the retroseptal approach, the incision through the periorbita is immediately posterior to the orbital rim. Periosteal elevators are used to strip the periosteum over the orbital rim and anterior surface of the maxilla and zygoma, and the orbital floor. A broad malleable retractor should be placed as soon as feasible to protect the orbit and to confine any herniating periorbital fat.

For Study group: After identification of the floor defect, Patient-Specific titanium mesh that will be manufactured and printed by CAD-CAM technology to cover the defect and will be seated by the operator and assure that there is no entrapment of tissue underneath the mesh.

In Control group: In preparation of the patient, hair may or may not be shaved, depending on the clinical situation.

If exposure of zygomatic arch, orbital rim or temporomandibular joint will be also needed, a coronal incision will be designed, the coronal flaps may be retracted to expose the parietal region. A vasoconstrictor will be injected into the subgaleal plane to promote hemostasis and to help separate the tissue layers. Another technique for hemostasis involves inserting running blocking sutures of 2-0 polypropylene or nylon along each side of the proposed incision line. These sutures will be removed at the completion of scalp closure. the last technique, special cautery scalpels are used for scalp incisions, but these heated scalpels may damage hair follicles.

Otherwise, a laterally placed incision in the parieto-temporal region is used. If possible, the incision should be designed away from the graft site, as there is a tendency for the incision to scar down to the underlying graft bed.

The surgical guide will be positioned and checked for stability and accuracy. The borders of the required graft will be marked using a micro-disk, and then the osteotomy will be further deepened to the spongy diploe of the skull bone. Once the required level is reached, undermining will be performed with bone chisels until the outer table of the bone lock is freed, then the bone block will be inserted and seated on the Printed Skull Model to assure stability and then inserted on orbital floor to cover the defect and prevent any entrapment of orbital fibrous-adipose-muscular tissues. The surgical field will be rinsed with saline and then closed by absorbable sutures, followed by cutaneous needles stapled to the skin of the scalp.

In both groups:

Forced duction test will be repeated to rule out iatrogenic entrapment, and the position of the orbital floor implant will be once again checked to ensure that no migration had occurred during the forced duction testing.

Inferior canthopexy suture will be inserted but not tied, the conjunctiva then sutured, a 4-0 polyglactin or other long-lasting suture is used to reattach the lateral portion of the inferior tarsal plate to the residual superior portion of the lateral canthal tendon or to the fixed surrounding tissues.

The suture through the lateral border of the lower tarsus and/or cut portion of the lateral canthal tendon may be facilitated by elevating the skin sharply with a blade No 15, slightly atop the canthus or tarsal plate. The conjunctiva should be closed with a running 6-0 chromic gut suture. The ends of the suture may be buried. The inferior canthopexy suture is then tightened and tied, drawing the lower eyelid into position. Finally, subcutaneous sutures and 6-0 skin sutures are placed along the horizontal lateral canthotomy.

02

Conditions studied

  • Orbital Floor (Blow-Out) Open Fracture
  • Enophthalmos Traumatic

Keywords

  • Blow-out Fracture, Orbital floor Fracture , Orbital Floor Reconstruction
03

In context

Fractures, Open

53 studies on the registry are indexed under Fractures, Open; 14 are open to participants now.

This study's planned enrollment of 32 is below the median of 90 across 40 interventional studies indexed under Fractures, Open.

Browse Fractures, Open studies →

Lead sponsor

This is the only study on the registry with Mohammed Ghassan Mohammed Shaalan as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with previous fresh maxillofacial trauma within 14 days affecting zygomatic bones and orbital walls.
  • Patients with medical history that did not hinder previous reconstruction of orbital floor defect.
  • Both genders males and females will be included.

Exclusion criteria

Exclusion Criteria:

  • Patients with craniofacial anomalies or syndromes.
  • Subjected to irradiation in the head and neck area less than 6 months to -1 year before procedure
  • Pregnant or nursing females.
  • Psychiatric problems or unrealistic expectations.
  • or immunocompromised patients.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    Orbital Volume After Using Guided Calvarial Graft in Floor Recontsruction

    Device: orbital floor recontriction

  • Experimental
    Orbital Volume After Using 3D Printed Titanium mesh in Floor Recontsruction

    Device: orbital floor recontriction

Interventions

  • Deviceorbital floor recontriction

    Guided Calvarial Graft Harvesting vs 3D Printed Titanium mesh

06

What researchers measure

Primary outcomes

  1. Orbital volume Measuring

    Time frame: Immediately Post Operative

07

Study locations

1 site
  • Mohammed Ghassan Mohammed Shaalan
    Cairo, Manial 11553, Egypt
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2021 (actual). Primary completion is estimated for Jan 2023, 16 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2022
First posted
Sep 22, 2022
StartActual
Sep 1, 2021
Primary completionEst.
Jan 1, 2023
CompletionEst.
Jan 1, 2023
Last update
Sep 22, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05550285
Lead sponsor
Mohammed Ghassan Mohammed Shaalan
Responsible party
Mohammed Ghassan Mohammed Shaalan (Master Student, Cairo University) — Sponsor-investigator
First posted
Sep 22, 2022
Start date
Sep 1, 2021
Primary completion
Jan 1, 2023 (estimated)
Completion
Jan 1, 2023 (estimated)
Last update
Sep 22, 2022

Study contacts

Mohamed Farid Shehab, Professor
study director · Professor, Oral & Maxillofacial surgery, Cairo University
Heba Mohamed Kamel, Assistant Professor
study director · Assistant professor, Oral & Maxillofacial surgery, Cairo University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion